All patients
Age < 65y (younger) Age > 65y Age > 75y (older) Asian type cancer location (gastric) cancer location (gastro-esophageal) ECOG 0 ECOG 1 Gender, female Gender, male metastasis (liver ) PD-L1 < 1% PD-L1 > 1% previous gastrectomy previous gastrectomy NO
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
mGC or mGEJC - L2 - all population, immune chekpoint inhibitors vs. chemotherapy, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results CA184-162, 2017 1.54 [0.73; 3.26]
JAVELIN Gastric 300, 2018 1.10 [0.88; 1.37]
KEYNOTE-061 (all population), 2018 0.94 [0.79; 1.12]
1.02 [0.87 ; 1.20 ] CA184-162, 2017, JAVELIN Gastric 300, 2018, KEYNOTE-061 (all population), 2018 3 19% 1,077 moderate not evaluable progression or deaths (PFS)detailed results CA184-162, 2017 1.59 [1.20; 2.10]
JAVELIN Gastric 300, 2018 1.73 [1.38; 2.17]
KEYNOTE-061 (all population), 2018 1.49 [1.25; 1.77]
1.58 [1.39 ; 1.79 ] CA184-162, 2017, JAVELIN Gastric 300, 2018, KEYNOTE-061 (all population), 2018 3 0% 1,077 moderate not evaluable DCRdetailed results JAVELIN Gastric 300, 2018 0.37 [0.23; 0.60]
0.37 [0.23 ; 0.60 ] JAVELIN Gastric 300, 2018 1 0% 371 NA not evaluable irORRdetailed results CA184-162, 2017 0.24 [0.03; 2.19]
0.24 [0.03 ; 2.19 ] CA184-162, 2017 1 0% 114 NA not evaluable irPFSdetailed results CA184-162, 2017 1.44 [1.09; 1.91]
1.44 [1.09 ; 1.91 ] CA184-162, 2017 1 0% 114 NA not evaluable objective responses (ORR)detailed results JAVELIN Gastric 300, 2018 0.49 [0.15; 1.66]
KEYNOTE-061 (all population), 2018 0.88 [0.53; 1.45]
0.81 [0.51 ; 1.28 ] JAVELIN Gastric 300, 2018, KEYNOTE-061 (all population), 2018 2 0% 963 moderate not evaluable TRAE (any grade)detailed results CA184-162, 2017 2.05 [0.90; 4.67]
JAVELIN Gastric 300, 2018 0.34 [0.22; 0.52]
KEYNOTE-061 (all population), 2018 0.21 [0.14; 0.31]
0.49 [0.18 ; 1.37 ] CA184-162, 2017, JAVELIN Gastric 300, 2018, KEYNOTE-061 (all population), 2018 3 92% 1,033 moderate not evaluable TRAE (grade 3-4)detailed results CA184-162, 2017 3.03 [0.91; 10.04]
JAVELIN Gastric 300, 2018 0.22 [0.12; 0.40]
KEYNOTE-061 (all population), 2018 0.31 [0.21; 0.47]
0.50 [0.18 ; 1.41 ] CA184-162, 2017, JAVELIN Gastric 300, 2018, KEYNOTE-061 (all population), 2018 3 87% 1,033 moderate not evaluable TRAE leading to death (grade 5)detailed results CA184-162, 2017 1.92 [0.55; 6.70]
JAVELIN Gastric 300, 2018 0.48 [0.02; 14.39]
KEYNOTE-061 (all population), 2018 2.84 [0.29; 27.42]
1.83 [0.65 ; 5.19 ] CA184-162, 2017, JAVELIN Gastric 300, 2018, KEYNOTE-061 (all population), 2018 3 0% 1,033 moderate not evaluable TRAE leading to discontinuation (any grade)detailed results CA184-162, 2017 1.00 [0.02; 51.28]
JAVELIN Gastric 300, 2018 0.74 [0.27; 2.03]
KEYNOTE-061 (all population), 2018 0.55 [0.24; 1.28]
0.63 [0.33 ; 1.19 ] CA184-162, 2017, JAVELIN Gastric 300, 2018, KEYNOTE-061 (all population), 2018 3 0% 1,045 moderate not evaluable Alopecia TRAE (grade 3-4)detailed results JAVELIN Gastric 300, 2018 0.96 [0.02; 48.74]
KEYNOTE-061 (all population), 2018 0.16 [0.01; 3.11]
0.30 [0.03 ; 3.29 ] JAVELIN Gastric 300, 2018, KEYNOTE-061 (all population), 2018 2 0% 931 moderate not evaluable Anaemia TRAE (grade 3-4)detailed results JAVELIN Gastric 300, 2018 0.04 [0.00; 0.71]
KEYNOTE-061 (all population), 2018 0.54 [0.21; 1.38]
0.21 [0.02 ; 2.39 ] JAVELIN Gastric 300, 2018, KEYNOTE-061 (all population), 2018 2 65% 931 moderate not evaluable Asthenia TRAE (grade 3-4)detailed results CA184-162, 2017 1.59 [0.05; 48.47]
JAVELIN Gastric 300, 2018 0.19 [0.02; 1.63]
0.36 [0.05 ; 2.42 ] CA184-162, 2017, JAVELIN Gastric 300, 2018 2 7% 463 moderate not evaluable Colitis TRAE (grade 3-4)detailed results CA184-162, 2017 4.94 [0.24; 101.33]
KEYNOTE-061 (all population), 2018 0.16 [0.01; 3.11]
0.87 [0.03 ; 25.93 ] CA184-162, 2017, KEYNOTE-061 (all population), 2018 2 61% 672 moderate not evaluable Decreased appetite TRAE (grade 3-4)detailed results CA184-162, 2017 1.59 [0.05; 48.47]
JAVELIN Gastric 300, 2018 0.12 [0.01; 2.25]
KEYNOTE-061 (all population), 2018 3.77 [0.17; 84.06]
0.82 [0.10 ; 6.89 ] CA184-162, 2017, JAVELIN Gastric 300, 2018, KEYNOTE-061 (all population), 2018 3 27% 1,033 moderate not evaluable Diabetes TRAE (grade 3-4)detailed results KEYNOTE-061 (all population), 2018 0.94 [0.02; 47.47]
0.94 [0.02 ; 47.47 ] KEYNOTE-061 (all population), 2018 1 0% 570 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results CA184-162, 2017 8.56 [0.45; 161.00]
JAVELIN Gastric 300, 2018 0.16 [0.02; 1.31]
KEYNOTE-061 (all population), 2018 0.94 [0.06; 15.08]
0.91 [0.09 ; 9.13 ] CA184-162, 2017, JAVELIN Gastric 300, 2018, KEYNOTE-061 (all population), 2018 3 58% 1,033 moderate not evaluable Endocrine disorders TRAE (grade 3-4) detailed results CA184-162, 2017 0.79 [0.02; 40.48]
0.79 [0.02 ; 40.48 ] CA184-162, 2017 1 0% 102 NA not evaluable Fatigue TRAE (grade 3-4)detailed results CA184-162, 2017 3.24 [0.14; 73.60]
JAVELIN Gastric 300, 2018 0.48 [0.04; 5.32]
KEYNOTE-061 (all population), 2018 0.49 [0.19; 1.26]
0.56 [0.24 ; 1.30 ] CA184-162, 2017, JAVELIN Gastric 300, 2018, KEYNOTE-061 (all population), 2018 3 0% 1,033 moderate not evaluable Febrile neutropenia TRAE (grade 3-4)detailed results JAVELIN Gastric 300, 2018 0.08 [0.00; 1.40]
0.08 [0.00 ; 1.40 ] JAVELIN Gastric 300, 2018 1 0% 361 NA not evaluable Hepatitis TRAE (grade 3-4)detailed results KEYNOTE-061 (all population), 2018 7.60 [0.40; 144.43]
7.60 [0.40 ; 144.43 ] KEYNOTE-061 (all population), 2018 1 0% 570 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results KEYNOTE-061 (all population), 2018 0.94 [0.02; 47.47]
0.94 [0.02 ; 47.47 ] KEYNOTE-061 (all population), 2018 1 0% 570 NA not evaluable Hypophysitis TRAE (grade 3-4)detailed results KEYNOTE-061 (all population), 2018 3.77 [0.17; 84.06]
3.77 [0.17 ; 84.06 ] KEYNOTE-061 (all population), 2018 1 0% 570 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results CA184-162, 2017 3.24 [0.14; 73.60]
KEYNOTE-061 (all population), 2018 0.94 [0.02; 47.47]
2.00 [0.17 ; 23.06 ] CA184-162, 2017, KEYNOTE-061 (all population), 2018 2 0% 672 moderate not evaluable Increase AST TRAE (grade 3-4)detailed results JAVELIN Gastric 300, 2018 1.29 [0.28; 5.84]
1.29 [0.28 ; 5.84 ] JAVELIN Gastric 300, 2018 1 0% 361 NA not evaluable Increased ALT TRAE (grade 3-4)detailed results JAVELIN Gastric 300, 2018 0.72 [0.16; 3.25]
0.72 [0.16 ; 3.25 ] JAVELIN Gastric 300, 2018 1 0% 361 NA not evaluable Increased lipase level TRAE (grade 3-4)detailed results JAVELIN Gastric 300, 2018 0.48 [0.04; 5.32]
0.48 [0.04 ; 5.32 ] JAVELIN Gastric 300, 2018 1 0% 361 NA not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results JAVELIN Gastric 300, 2018 1.93 [0.06; 57.86]
KEYNOTE-061 (all population), 2018 0.47 [0.02; 14.02]
0.95 [0.09 ; 10.52 ] JAVELIN Gastric 300, 2018, KEYNOTE-061 (all population), 2018 2 0% 931 moderate not evaluable Myalgia TRAE (grade 3-4)detailed results CA184-162, 2017 0.79 [0.02; 40.48]
0.79 [0.02 ; 40.48 ] CA184-162, 2017 1 0% 102 NA not evaluable Nausea TRAE (grade 3-4)detailed results CA184-162, 2017 0.79 [0.02; 40.48]
JAVELIN Gastric 300, 2018 0.24 [0.01; 5.32]
KEYNOTE-061 (all population), 2018 0.47 [0.04; 5.19]
0.42 [0.08 ; 2.33 ] CA184-162, 2017, JAVELIN Gastric 300, 2018, KEYNOTE-061 (all population), 2018 3 0% 1,033 moderate not evaluable Neutropenia TRAE (grade 3-4)detailed results JAVELIN Gastric 300, 2018 0.02 [0.00; 0.30]
KEYNOTE-061 (all population), 2018 0.02 [0.00; 0.25]
0.02 [0.00 ; 0.12 ] JAVELIN Gastric 300, 2018, KEYNOTE-061 (all population), 2018 2 0% 931 moderate not evaluable Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4)detailed results CA184-162, 2017 0.19 [0.01; 4.33]
0.19 [0.01 ; 4.33 ] CA184-162, 2017 1 0% 102 NA not evaluable Pancreatitis TRAE (grade 3-4)detailed results KEYNOTE-061 (all population), 2018 0.47 [0.02; 14.02]
0.47 [0.02 ; 14.02 ] KEYNOTE-061 (all population), 2018 1 0% 570 NA not evaluable Peripheral neuropathy TRAE (grade 3-4)detailed results CA184-162, 2017 0.79 [0.02; 40.48]
KEYNOTE-061 (all population), 2018 0.08 [0.00; 1.38]
0.17 [0.02 ; 1.78 ] CA184-162, 2017, KEYNOTE-061 (all population), 2018 2 0% 672 moderate not evaluable Pneumonitis TRAE (grade 3-4)detailed results KEYNOTE-061 (all population), 2018 3.77 [0.17; 84.06]
3.77 [0.17 ; 84.06 ] KEYNOTE-061 (all population), 2018 1 0% 570 NA not evaluable Pruritus TRAE (grade 3-4)detailed results CA184-162, 2017 0.79 [0.02; 40.48]
0.79 [0.02 ; 40.48 ] CA184-162, 2017 1 0% 102 NA not evaluable Rash TRAE (grade 3-4)detailed results CA184-162, 2017 0.79 [0.02; 40.48]
0.79 [0.02 ; 40.48 ] CA184-162, 2017 1 0% 102 NA not evaluable Severe skin reaction TRAE (grade 3-4)detailed results KEYNOTE-061 (all population), 2018 1.88 [0.06; 56.28]
1.88 [0.06 ; 56.28 ] KEYNOTE-061 (all population), 2018 1 0% 570 NA not evaluable Vomiting TRAE (grade 3-4)detailed results CA184-162, 2017 0.79 [0.02; 40.48]
JAVELIN Gastric 300, 2018 0.24 [0.01; 5.32]
0.38 [0.03 ; 4.32 ] CA184-162, 2017, JAVELIN Gastric 300, 2018 2 0% 463 moderate not evaluable Weight decreased TRAE (grade 3-4)detailed results JAVELIN Gastric 300, 2018 0.07 [0.00; 1.17]
0.07 [0.00 ; 1.17 ] JAVELIN Gastric 300, 2018 1 0% 361 NA not evaluable 0.0 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-07-03 19:48 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 123
- treatments: 204,504,850,329,558,579,549,868,502,741,556,812,813,367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,854,374,1073,953,672,1080,862,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258,746,745,856,634,861,416,864,769,980,369,743
